Verona Pharma Investor Relations Material
Latest events
Q1 2025
Verona Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Verona Pharma plc
Access all reports
Verona Pharma plc is a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of respiratory diseases. Its main product, ensifentrine, is designed to alleviate symptoms and improve health outcomes in conditions such as chronic obstructive pulmonary disease (COPD). The company is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Key slides for Verona Pharma plc
Company Presentation
Verona Pharma plc
Company Presentation
Verona Pharma plc
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
VRNA
Country
🇺🇸 United States